HTA submission round-up
Thursday, March 31, 2016
We’ve had another busy year working with pharmaceutical and biotech company clients to produce high-quality, robust dossiers of evidence to reimbursement authorities in the UK and Ireland. In the last 12 months alone, we have helped clients submit a total of ten dossiers to NICE, the SMC, the AWMSG and the NCPE, for six different products in oncology, mental health, rare genetic conditions and anti-infectives. In each case, HJCL played a significant role in writing the submission and/or overall project management. We can also support companies on HTA process and training, stakeholder management, HTA communications and lobbying, Patient Access Schemes and appeal hearing preparation.